当前位置: X-MOL 学术Nat. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effectiveness of CoronaVac in children 3 to 5 years during the SARS-CoV-2 Omicron outbreak in Chile
Nature Medicine ( IF 82.9 ) Pub Date : 2022-05-23 , DOI: 10.1038/s41591-022-01874-4
Alejandro Jara 1, 2, 3 , Eduardo A Undurraga 4, 5, 6, 7 , José R Zubizarreta 8, 9, 10 , Cecilia González 1 , Johanna Acevedo 1 , Alejandra Pizarro 1, 11 , Verónica Vergara 1 , Mario Soto-Marchant 1 , Rosario Gilabert 1 , Juan Carlos Flores 11 , Pamela Suárez 1 , Paulina Leighton 1 , Pablo Eguiguren 1 , Juan Carlos Ríos 1, 11 , Jorge Fernandez 1 , Heriberto García-Escorza 1 , Rafael Araos 1, 5, 12, 13
Affiliation  

The outbreak of the B.1.1.529 lineage of SARS-CoV-2 (Omicron) has caused an unprecedented number of COVID-19 cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3-5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac’s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization, and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between December 6, 2021, and February 26, 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence intervals, CI, 36.5–39.9) against symptomatic COVID-19, 64.6% (95%CI, 49.6–75.2) against hospitalization, and 69.0% (95%CI, 18.6–88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest. However, protection against severe disease was high. These results support vaccination of children 3-5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.



中文翻译:

智利 SARS-CoV-2 Omicron 爆发期间 CoronaVac 对 3 至 5 岁儿童的有效性

SARS-CoV-2 (Omicron) 的 B.1.1.529 谱系的爆发导致了史无前例的 COVID-19 病例数,包括儿科住院病例。政策制定者迫切需要儿童疫苗有效性的证据,以平衡疫苗接种运动的成本和收益,但迄今为止,证据很少。我们利用智利 490,694 名 3-5 岁儿童的基于人群的队列,估计了相隔 28 天的两剂计划施用科兴生物灭活 SARS-CoV-2 疫苗 (CoronaVac) 的有效性。我们使用逆概率加权生存回归模型来估计有症状的 COVID-19、住院和入住重症监护病房 (ICU) 的儿童完全免疫与未接种疫苗的风险比,考虑随时间变化的疫苗接种暴露和相关混杂因素。该研究于 2021 年 12 月 6 日至 2022 年 2 月 26 日在智利 Omicron 爆发期间进行。对有症状的 COVID-19 的估计疫苗有效性为 38.2%(95% 置信区间,CI,36.5-39.9),对住院治疗的有效性为 64.6%(95%CI,49.6-75.2)和 69.0%(95%CI,18.6-88.2) ) 反对 ICU 入院。对有症状的 COVID-19 的有效性是适度的。然而,对严重疾病的保护能力很高。这些结果支持对 3-5 岁儿童进行疫苗接种,以预防严重疾病和相关并发症,并强调维持针对 SARS-CoV-2 感染的分层保护的重要性。对有症状的 COVID-19 的估计疫苗有效性为 38.2%(95% 置信区间,CI,36.5-39.9),对住院治疗的有效性为 64.6%(95%CI,49.6-75.2)和 69.0%(95%CI,18.6-88.2) ) 反对 ICU 入院。对有症状的 COVID-19 的有效性是适度的。然而,对严重疾病的保护能力很高。这些结果支持对 3-5 岁儿童进行疫苗接种,以预防严重疾病和相关并发症,并强调维持针对 SARS-CoV-2 感染的分层保护的重要性。对有症状的 COVID-19 的估计疫苗有效性为 38.2%(95% 置信区间,CI,36.5-39.9),对住院治疗的有效性为 64.6%(95%CI,49.6-75.2)和 69.0%(95%CI,18.6-88.2) ) 反对 ICU 入院。对有症状的 COVID-19 的有效性是适度的。然而,对严重疾病的保护能力很高。这些结果支持对 3-5 岁儿童进行疫苗接种,以预防严重疾病和相关并发症,并强调维持针对 SARS-CoV-2 感染的分层保护的重要性。

更新日期:2022-05-24
down
wechat
bug